Tzield Approval Expands to Younger Patients First disease-modifying option available for children as young as 1 year with stage 2 type 1 diabetes By Kathryn Wighton April 22, 2026 2 min Conexiant Share Summary Listen Insight Report Clinical Scorecard Quiz Top Institutions